These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 23016674)

  • 1. Role of asymmetrical dimethylarginine in the progression of renal disease.
    Raptis V; Kapoulas S; Grekas D
    Nephrology (Carlton); 2013 Jan; 18(1):11-21. PubMed ID: 23016674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pathways to renal damage: role of ADMA in retarding renal disease progression.
    Ueda S; Yamagishi S; Okuda S
    J Nephrol; 2010; 23(4):377-86. PubMed ID: 20349427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.
    Ueda S; Yamagishi S; Kaida Y; Okuda S
    Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
    Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
    Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
    Zoccali C; Kielstein JT
    Curr Opin Nephrol Hypertens; 2006 May; 15(3):314-20. PubMed ID: 16609301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
    Gilinskiĭ MA
    Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
    Kielstein JT; Zoccali C
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):609-15. PubMed ID: 18941355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
    Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
    Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance?
    Kielstein JT; Fliser D; Veldink H
    Semin Dial; 2009; 22(4):346-50. PubMed ID: 19708979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
    Fliser D
    Eur J Clin Invest; 2005 Feb; 35(2):71-9. PubMed ID: 15667575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of kaempferol against endothelial damage by an improvement in nitric oxide production and a decrease in asymmetric dimethylarginine level.
    Xiao HB; Jun-Fang ; Lu XY; Chen XJ; Chao-Tan ; Sun ZL
    Eur J Pharmacol; 2009 Aug; 616(1-3):213-22. PubMed ID: 19549512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?
    Schepers E; Speer T; Bode-Böger SM; Fliser D; Kielstein JT
    Semin Nephrol; 2014 Mar; 34(2):97-105. PubMed ID: 24780466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
    Selley ML
    J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of asymmetric dimethylarginine in cardiorenal syndrome.
    Ueda S; Yamagishi S; Yokoro M; Okuda S
    Curr Pharm Des; 2014; 20(14):2448-55. PubMed ID: 23844812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease.
    Fliser D
    J Nephrol; 2010; 23(4):369-76. PubMed ID: 20349425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric dimethylarginine: An crucial regulator in tissue fibrosis.
    Zhao WC; Li G; Huang CY; Jiang JL
    Eur J Pharmacol; 2019 Jul; 854():54-61. PubMed ID: 30951718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?
    Kielstein JT; Frölich JC; Haller H; Fliser D
    Nephrol Dial Transplant; 2001 Sep; 16(9):1742-5. PubMed ID: 11522849
    [No Abstract]   [Full Text] [Related]  

  • 20. Asymmetric dimethylarginine and kidney disease--marker or mediator?
    Vallance P; Leiper J
    J Am Soc Nephrol; 2005 Aug; 16(8):2254-6. PubMed ID: 15987745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.